Heart attack survivors with gene variant may benefit from colchicine

NCT ID NCT07362966

Recruiting now Disease control Sponsor: Shenyang Northern Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This pilot study tests whether the drug colchicine can reduce artery plaque in 120 heart attack survivors who have a specific genetic change (TET2-CHIP). Participants take colchicine or standard care for 12 months. The goal is to see if this genetic marker can guide personalized treatment for heart disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: colchicine
What this could lead to: If successful, this could show that colchicine works better for people with a specific genetic marker, leading to more personalized heart disease treatment.
What could go wrong: This is a small pilot study, so results may not be conclusive. Colchicine can cause side effects like stomach upset, and it's not yet proven to reduce heart attacks in this group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome clonal hematopoiesis of indeterminate potential colchicine poisoning coronary atherosclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL COLCHICINE CORONARY ATHEROSCLEROSIS MANAGEMENT

Contacts and locations

Locations

General Hospital of Northern Theater Command
RECRUITING

Shenyang, Liaoning, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.